AJAtakan Jordan

Atakan Jordan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Atakan Jordan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Emma Kruger

    Department of Dermatology, University of Cape Town, Cape Town, South Africa

    1 shared publication
  • Georgios Kokolakis

    Psoriasis Research and Treatment Centre, Charité – Universitätsmedizin Berlin, Berlin, Germany

    1 shared publication
  • Hanna Bonnekoh

    Institute of Allergology, Charité – University Medical Center Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

    1 shared publication
  • Lais Ferreira Lopes Brum

    Allergy and Immunology Department, Children’s Institute, University of São Paulo, São Paulo, Brazil

    1 shared publication
  • Lena Marie Böhm

    Institute of Allergology, Charité – University Medical Center Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

    1 shared publication
  • Martin Metz

    Institute of Allergology Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany

    1 shared publication

Latest Publications

  • Open Access

    Modern Systemic Therapies for Psoriasis in Active-Duty German Soldiers: A Retrospective Single-Center Study of Treatment Outcomes and Service-Wide Operational Burden

    by Atakan Jordan, Georgios Kokolakis, Staffan Vandersee

    Purpose: Several armed forces treat psoriasis as a categorical barrier to service, and systemic therapy can preclude enlistment or restrict deployment. These standards predate interleukin-17 and interleukin-23 inhibitors. We assessed efficacy, safety and drug survival of modern versus conventional systemic therapies in active-duty soldiers, and the psoriasis-attributable operational burden in the German Armed Forces. Patients and Methods: Single-center retrospective cohort study. Of 142 active-duty soldiers with psoriasis seen in 2019– 2023, 77 had received systemic therapy between 2004 and 2023 (first line 49 modern, 28 conventional, 127 treatment cycles in total). Endpoints were estimated Investigator Global Assessment (IGA) at initiation and at the last visit on first-line therapy, adverse events (CTCAE version 6.0), and drug survival (Kaplan–Meier and Cox regression). Operational outcomes came from four service-wide registries not linked to the cohort. Results: Mean estimated IGA improved by 2.0 points under first-line modern versus 0.8 points under conventional therapy (P < 0.001), and complete clearance (IGA 0) was reached by 38/49 (78%) versus 1/28 (3.6%) (P < 0.001). Adverse events caused discontinuation in 2/97 (2.1%) modern versus 14/30 (46.7%) conventional cycles (P < 0.001). No grade 3 or 4 laboratory abnormality occurred (0/60, 95% CI 0– 6.0%). Modern therapy was associated with less discontinuation or switching (first-line hazard ratio 0.17, 95% CI 0.08– 0.33; calendar-year adjusted 0.10, 95% CI 0.05– 0.23). Service-wide, no declaration of permanent unfitness for service due to psoriasis was recorded over 20 years, and psoriasis caused 4 of 7096 repatriations (0.056%). Of 87 diving-fitness assessments documenting psoriasis, among 15,718 in total, one (1.1%) was negative, owing to psoriatic arthritis. Conclusion: In this single-center military cohort, modern systemic therapies were associated with higher clearance, fewer adverse-event discontinuations and longer drug survival. Service-wide data showed a low observed psoriasis-attributable operational burden. These findings support giving demonstrated treatment response greater weight in individualized military fitness assessment. Plain Language Summary: Psoriasis is a lifelong skin disease. In several countries a soldier who needs tablets or injections to control it can be barred from service or from going on deployment. These rules were written before today’s targeted drugs existed. We reviewed the records of 142 German soldiers with psoriasis treated at one military hospital. Modern targeted drugs cleared the skin completely in about 8 of every 10 soldiers, compared with fewer than 1 in 20 on older drugs. Soldiers also stayed on the modern drugs far longer, and far fewer stopped them because of side effects. Across the whole German armed forces, no soldier was declared permanently unfit for service because of psoriasis in 20 years, and only four of 7096 medical evacuations from deployment were caused by it. As a records-based study from one hospital, it shows how these treatments perform in everyday care rather than proving cause and effect. The results suggest that fitness decisions should take into account how well the disease is controlled with medication, and not only the diagnosis. Infographic with a header summary, four numbered sections and a concluding statement about psoriasis therapy in soldiers. Header summary: 142 soldiers with psoriasis, single center, 2019 to 2023, arrow to 77 on systemic therapy since 2004, arrow to 127 treatment cycles. First line: 49 modern (biologics, small molecules). 28 conventional (fumarates, methotrexate). 1 EFFICACY. Complete skin clearance, estimated IGA 0, first line. Modern: 78 percent (38 over 49). Conventional: 3.6 percent (1 over 28). P less than 0.001. Mean IGA reduction: 2.0 vs 0.8 points. 2 SAFETY. Stopped for adverse events, all treatment cycles. Modern: 2.1 percent (2 over 97). Conventional: 46.7 percent (14 over 30). P less than 0.001, exploratory. Laboratory toxicity (CTCAE): No grade greater than or equal to 3 (0 over 60). 3 DRUG SURVIVAL. Discontinuation or switch, modern vs conventional, first line. HR 0.17. 95 percent CI 0.08 to 0.33, P less than 0.001. calendar year adjusted HR 0.10. Median drug survival: 61.5 vs 9.0 months. 4 OPERATIONAL BURDEN. Service wide registries, not linked to the clinical cohort. 0 declarations of permanent unfitness for service due to psoriasis, 20 years. 4 over 7096 repatriations from deployment due to psoriasis (0.056 percent). 1 over 87 negative diving fitness decisions in soldiers with psoriasis (psoriatic arthritis). 0 negative flight fitness decisions due to psoriasis, 10 years. Bottom statement: Demonstrated treatment response should receive greater weight in individualized military fitness assessment. Retrospective single center data, prospective multicenter studies are needed.Infographic comparing modern versus conventional systemic psoriasis therapy outcomes in soldiers.

  • Open Access

    Understanding the Course of Urticaria: From Acute to Chronic and to Remission

    by Melissa Afshar-Bakshloo, Lena Marie Böhm, Emma Kruger, Laís Ferreira Lopes Brum, Atakan Jordan, Sophia Neisinger, Martin Metz, Hanna Bonnekoh

    Purpose of Review: This review aims to provide an overview and update on the current knowledge of acute (spontaneous) urticaria (AU) and chronic spontaneous urticaria (CSU), the underlying mechanisms that drive AU progression to CSU and remission, and characterize the existing knowledge gap. A summary of current and prospective treatment options serves to guide treatment decisions. Recent Findings: Cutaneous mast cells (MC) are known as central effector cells in AU and CSU pathogenesis. In CSU, the two established endotypes, type I “autoallergy”, defined by the production of IgE antibodies against autoantigens, and type IIb “autoimmunity”, characterized by the production of functional IgG autoantibodies targeting IgE or FcεRI on MCs, have contributed crucially to pathophysiological understanding. Currently, total IgE and IgG anti-TPO antibodies are the only biomarkers available, which are used in clinical practice to guide treatment decisions. With the characterization of Bruton’s tyrosine kinase, an intracellular signaling molecule, and Mas-related G protein-coupled receptor member X2, an IgE-independent activating receptor that represents a link between MCs and sensory nerve endings, novel insights in pathophysiology and promising potential treatment targets have been gained. Summary: The upstream mechanisms leading to MC activation in AU, the processes mediating either progression from AU to CSU or early resolution of AU, as well as the question of what drives remission in CSU remain largely unresolved. Ongoing research aims at identifying predictors of disease courses, characterizing mechanisms in non-autoallergic/autoimmune CSU, and establishing biomarkers for early risk stratification and personalized therapy.